Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
source https://finance.yahoo.com/news/adverum-reports-data-phase-wet-140602217.html?.tsrc=rss
blaineonline.finance.blog 